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postconditioning: 
from bench to bedside
preconditioning (IPC). The evolution of “conditioning” as a cardio-
protective strategy will be briefl y reviewed in this article. For a 
more comprehensive description of these endogenous cardio-
protective phenomena the reader is directed to the following 
comprehensive reviews.(2-6) 
ISCHAEMIC PRECONDITIONING: LABORATORY        
PHENOMENON TO CLINICAL APPLICATION
In 1986, Murry and colleagues(1) fi rst made the intriguing observa-
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INTRODUCTION                                                               
Coronary heart disease (CHD) is the leading cause of death world-
wide. Since 1990 more people in the world have died from CHD 
than from any other disease (World Health Organisation, WHO). 
In South Africa alone, CHD is the third leading cause of death 
behind HIV and cerebrovascular disease, being responsible for 
27 000 deaths in 2002 (WHO). New effective treatment strategies 
capable of improving clinical outcomes in CHD patients need to 
be developed to impact on this devastating affl iction. 
In this regard, the endogenous protection elicited by the heart’s 
ability to “condition” itself, has emerged as a powerful new 
treatment strategy for limiting myocardial injury, preserving left 
ventricular systolic function and potentially improving morbidity and 
mortality in patients with CHD. The concept of harnessing the 
ability of the heart to protect itself originated from a seminal 
experimental study by Murry and colleagues,(1) in which it was fi rst 
demonstrated that the heart could be rendered resistant to acute 
ischaemia-reperfusion injury by brief episodes of myocardial 
ischaemia and reperfusion – a phenomenon termed ischaemic 
Coronary heart disease (CHD) is the leading cause of death 
world-wide. Since 1990, more people in the world have died 
from CHD than from any other disease (World Health 
Organisation, WHO). “Conditioning” the heart to render it 
more resistant to the detrimental effects of acute ischaemia-
reperfusion injury harnesses the endogenous ability of the 
heart to protect itself. This can be achieved using various 
mechanical strategies including the application of brief 
episodes of ischaemia and reperfusion to either the heart 
itself (ischaemic preconditioning) or an organ/tissue remote 
from the heart (remote ischaemic preconditioning) prior 
to the sustained ischaemic insult. Importantly, this form of 
protection can be mimicked by pharmacological agents 
capable of recapitulating the protective effect of IPC 
(pharmacological preconditioning). Preconditioning-induced 
cardioprotection is clearly restricted to patients undergoing 
an anticipated ischaemic insult such as in patients undergoing 
cardiac surgery. In contrast, the other major form of 
“conditioning” termed postconditioning can be imple-
mented in patients presenting with an acute myocardial 
infarction after the onset of the sustained ischaemic insult. 
In this setting, myocardial reperfusion is interrupted with 
intermittent short-lived episodes of myocardial ischaemia 
applied to the heart itself (ischaemic postconditioning) or an 
organ or tissue remote from the heart (remote ischaemic 
postconditioning) – an effect which can again be mimicked by 
pharmacological agents (pharmacological postconditioning). 
This article will briefl y review these various forms of 
“conditioning” examining the underlying mechanistic 
pathways and their clinical application. SAHeart 2009; 6:24-29
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tion that subjecting the heart to four 5 minute occlusions of the 
circumfl ex coronary artery, interspersed with 5 minute periods of 
reperfusion, was able to reduce the size of a subsequent myocardial 
infarct by 75% – a phenomenon termed ischaemic preconditioning 
(IPC). This endogenous cardioprotective effect, is an ubiquitous 
endogenous response to a brief episode of acute ischaemia-
reperfusion injury having been reproduced in all species tested 
including humans and a variety of organs other than the heart 
including the kidney, liver, and brain.(2) IPC elicits two distinct 
windows of cardioprotection: the fi rst window (classical IPC) 
manifests immediately and wanes after 2-3 hours and is replaced 
by a Second Window of Protection (SWOP) which appears 
12-24 hours later and lasts 2-3 days.(7) This article will focus 
on classical IPC. For a comprehensive review of SWOP the 
reader is directed to the following reviews.(3,8)
The mechanistic pathways underlying ischaemic preconditioning 
have been the subject of intensive investigation since the endoge-
nous cardioprotective phenomenon was fi rst described in 1986. 
The current paradigm proposes that the IPC stimulus generates 
several substances including adenosine, bradykinin and opioids 
among others, which stimulate their respective receptors, recruiting 
a variety of signal transduction pathways the majority of which 
converge on the mitochondrion, which is widely believed to be 
the end-effector of cardioprotection. Clearly, it is beyond the 
scope of this article to mention all the different signalling pathways 
which have been implicated in IPC, but the major signalling path-
ways include phosphoinositide 3-kinase (PI3K)-Akt, mitogen-
activated protein kinase kinase 1/2-extracellular regulated kinase 
1/2 (MEK1/2-Erk1/2), p38 mitogen-activated protein kinase 
(p38 MAPK),(9-12) Janus kinases (JAKs) and Signal Transducers and 
Activators of Transcription (STATs),(13,14) cyclic guanosine mono-
phosphate (cGMP)-protein kinase G (PKG) and protein kinase C 
(reviewed in).(2) 
Interestingly, it transpires that the IPC stimulus has the ability to 
modify events occurring in the fi rst few minutes of myocardial 
reperfusion, thereby protecting the heart from myocardial 
reperfusion injury.(15,16) The identifi cation of the signalling pathways 
underlying IPC, has facilitated the use of pharmacological agents 
which are able to recapitulate the cardioprotection elicited by 
IPC (termed pharmacological preconditioning), thereby obviating 
the need for an invasive IPC protocol. Because IPC requires an 
intervention which can be implemented before the onset of the 
index myocardial ischaemia, their clinical application has been largely 
restricted to specifi c settings such as cardiac surgery, in which the 
ischaemic insult can be anticipated. 
  
In 1993, our research group(17) were the fi rst to apply the concept 
of IPC to the clinical setting of cardiac surgery. Prior to going on 
cardiopulmonary bypass, the aorta is clamped, thereby rendering 
the heart globally ischaemic. Following cardiopulmonary bypass, 
the clamp on the aorta is released allowing reperfusion of the 
heart. Despite optimal myocardial preservation techniques using 
intermittent cross-clamp fi brillation or cold-blood cardioplegia, a 
signifi cant amount of myocardial injury still occurs, resulting in the 
peri-operative release of cardiac enzymes, the release of which has 
been associated with worse short-term and long-term clinical 
outcomes.(18) Therefore, the setting of cardiac surgery provides for 
a controlled model of acute myocardial ischaemia-reperfusion 
injury for assessing the clinical effi cacy of various treatment 
strategies. However, it must be appreciated that other factors such 
as coronary micro-embolisation and direct handling of the heart 
may also contribute to the myocardial injury sustained during 
cardiac surgery. 
In the initial clinical study conducted by our research group, the IPC 
protocol, which was instituted prior to putting the heart on bypass, 
comprised clamping the aorta for 3 minutes to induce global 
myocardial ischaemia followed by unclamping of the aorta for 
2 minutes to allow myocardial reperfusion, a cycle which was 
repeated.(17) Compared to control, IPC was reported to preserve 
myocardial adenosine triphosphate (ATP) levels(17) and result in 
less peri-operative troponin-T release.(19) A number of clinical 
studies have confi rmed the cardioprotective benefi ts of IPC in 
terms of fewer ventricular arrhythmias, lower inotrope scores, less 
myocardial necrosis, and improved LV systolic function,(20-25) although 
not all the studies have been positive.(26,27) Even for patients 
undergoing off-pump coronary artery bypass (OPCAB) surgery, 
IPC has been reported to exert benefi cial effects.(28,29) A recent 
meta-analysis of 933 patients in 22 trials found that IPC resulted 
in less ventricular arrhythmias, lower inotrope score and shorter 
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intensive care unit stays.(30) However, the application of this IPC 
protocol is limited by its invasive nature and inherent risk for 
thromboembolism. As such, pharmacological agents such as 
adenosine, inhalational anaesthetics and bradykinin have been 
used to mimic IPC protection in patients undergoing cardiac 
surgery, but with mixed results (reviewed in).(31)    
 
The benefi ts of IPC are limited to clinical scenarios in which the 
index ischaemic event can be anticipated. For patients presenting 
with an acute myocardial infarction (AMI), an interventional 
strategy capable of eliciting cardioprotection after the onset of 
myocardial ischaemia and at the time of reperfusion is required. 
In this regard ischaemic postconditioning represents a treatment 
strategy capable of benefi ting AMI patients. 
ISCHAEMIC POSTCONDITIONING: EFFECTIVE          
CLINICAL CARDIOPROTECTION
In 2003, Zhao and colleagues(32) fi rst introduced ischaemic 
postconditioning (IPost) as a mechanical interventional strategy 
comprising interrupting myocardial reperfusion with intermittent 
episodes of myocardial ischaemia, capable of preventing lethal 
reperfusion injury and reducing myocardial infarct size in the 
canine heart. In this landmark experimental study, following a 
sustained episode of left anterior descending coronary artery 
occlusion, IPost comprised interrupting myocardial reperfusion 
with three-30 second episodes of myocardial ischaemia and 
reperfusion, a manoeuvre which resulted in a dramatic reduction in 
myocardial infarct size to a level comparable to that elicited by 
ischaemic preconditioning.(32) Interestingly, modifying myocardial 
reperfusion by gradually reperfusing the heart had been previously 
reported to limit myocardial infarct size.(33,34) In fact, the term 
postconditioning had been previously used to refer to the anti-
arrhythmic effect of intermittent reperfusion in the feline heart.(35) 
Providing the IPost protocol is modifi ed appropriately, most 
animal hearts appear amenable to IPost, including human 
myocardium.(36,37) Other organs in which IPost has reported to 
be benefi cial include, the brain,(38) kidney(39) and liver.(40) As well as 
reducing myocardial infarct size, IPost has been demonstrated 
to exert a broad range of benefi cial effects including reducing 
oxidative stress, reducing cellular calcium accumulation, maintaining 
endothelial function, reducing neutrophil accumulation, attenuating 
apoptotic cell death and inhibiting mitochondrial permeability 
transition pore (mPTP) opening (reviewed in).(5,41)  
The introduction of IPost as a mechanical treatment intervention 
which can be applied at the onset of myocardial reperfusion, has 
not only regenerated interest in the myocardial reperfusion phase 
as a target for cardioprotection, but has also demonstrated the 
existence of lethal reperfusion injury in man. In several small clinical 
studies comprising patients presenting with an ST-elevation 
myocardial infarction (STEMI), IPost has been demonstrated to be 
clinically effective in terms of reducing myocardial infarct size 
acutely (assessed by cardiac enzymes). At one week and at 6 weeks 
by Single Photon Emission Computed Tomography (SPECT) 
analysis, and improving left ventricular (LV) systolic function 
(by echocardiography) at one year.(37,42,43) In these proof-of-
concept clinical studies, in the STEMI patients randomised to 
receive IPost, following stent-deployment in the infarct-related 
coronary artery, the angioplasty balloon was withdrawn upstream 
of the stent and infl ated for 1 minute to a low-pressure and 
then defl ated for 1 minute, a cycle which was repeated 4 times. 
This invasive protocol interrupted normal myocardial reperfusion 
with intermittent episodes of coronary artery re-occlusion.(37,42,43) 
  
Emerging clinical studies suggest that the concept of IPost may be 
benefi cial in patients undergoing cardiopulmonary bypass surgery. 
Releasing the aortic clamp following cardiopulmonary bypass 
subjects the heart to global ischaemia-reperfusion injury, which 
can be measured by the release of cardiac enzymes. Several small 
proof-of-concept clinical studies have reported that applying brief 
episodes of aortic clamping and declamping at this time can reduce 
myocardial injury in patients undergoing cardiac surgery.(44-47) 
Clearly, one can envisage this invasive treatment strategy potentially 
benefi ting children undergoing cardiac surgery, but for adult 
patients with atherosclerotic aortas, such an invasive post-
conditioning protocol being applied to the aorta may result in 
thromboembolic complications.   
  
The mechanism underlying IPost is under intensive investigation 
with experimental studies suggesting a three-tiered signalling 
cascade, initiated by ligand-binding at particular specifi c receptors 
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which include the adenosine, bradykinin, natriuretic peptide, opioid 
and platelet-activating factor receptors, followed by the activation 
of signalling pathways which include the Reperfusion Injury 
Salvage Kinase (RISK) pathway, and fi nally the mitochondria as 
end-effectors of cardioprotection.(5,48) It is clear that many of 
the signalling components implicated in IPost protection are 
recruited by IPC. The important implication of this being that it 
is possible to mimic protection elicited by either IPC or IPost by 
administering pharmacological agents at reperfusion which target 
specifi c components of this cardioprotective signalling pathway-so-
termed pharmacological postconditioning. In this regard, pharma-
cological targeting of the RISK pathway by a diverse variety of 
pharmacological agents has the ability to reduce myocardial 
infarct size in experimental animal models(49,50) and inhibiting mPTP 
opening has been recently demonstrated to be benefi cial in 
AMI patients undergoing primary PCI.(51) Both IPC and IPost 
require invasive cardioprotective strategies applied to the myo-
cardium itself, thereby limiting their clinical applicability. The 
important fi nding that myocardial protection can be elicited at 
a distance, away from the heart, has given rise to the concept 
of remote ischaemic conditioning of the heart. 
REMOTE ISCHAEMIC PRECONDITIONING:               
GIVING YOUR RIGHT ARM TO PROTECT YOUR HEART 
In 1993, Pryzklenk and colleagues(52) made the intriguing observa-
tion that the preconditioning effect elicited by brief ischaemia in 
the circumfl ex artery territory could actually be manifested in 
myocardium supplied by the left anterior descending artery 
territory, indicating for the fi rst time that protection could be 
conveyed from one region of the heart to another. This concept 
has been further evolved and developed to extend to organs and 
tissue distant from the heart such as the kidney, small intestine, 
liver, and the limbs, such that brief episodes of ischaemia and 
reperfusion applied to these organs or tissue have been reported 
to protect against myocardial infarction – a phenomenon termed 
remote ischaemic preconditioning (RIPC) (reviewed in).(6) Indeed, 
remote ischaemic preconditioning appears to confer multi-organ 
protection against acute ischaemia-reperfusion injury. 
The mechanisms underlying this intriguing protective phenomenon 
are unclear but it has been postulated that many of the protective 
mechanisms implicated in conventional myocardial preconditioning 
are recruited in RIPC. The mystery surrounds the mechanistic 
pathway linking the remote preconditioning organ or tissue to 
the heart. Two mechanisms which has been proposed to link the 
preconditioning organ or tissue with the myocardial protection 
include a neural pathway and a hormonal pathway, but the two 
are not mutually exclusive given that the most popular paradigm 
proposes that substances generated locally such as adenosine or 
bradykinin within the preconditioned organ or tissue stimulate 
local neural pathways, which then activate neural pathways that 
terminate at the heart capable of activating endogenous myocardial 
protective pathways either directly or through the release of 
other substances such as bradykinin or noradrenaline.(6) 
  
The discovery that myocardial infarct size could be limited by 
applying brief episodes of ischaemia and reperfusion to the lower 
limb(53) resulted in the development of a non-invasive strategy for 
eliciting RIPC in the clinical arena.(54,55) We and others have 
demonstrated that brief episodes of ischaemia and reperfusion 
applied to either the upper limb (non-invasively using a blood 
pressure cuff) or the lower limb (by invasive clamping of the iliac 
arteries) is capable of reducing myocardial injury in patients 
undergoing cardiac surgery(56,57) or surgical repair of an abdominal 
aortic aneurysm.(58) Interestingly, Ali and colleagues(58) were able 
to demonstrated renal protection using RIPC of the lower-limb in 
addition to myocardial protection. Clearly, further multi-centred 
clinical studies are required to determine whether RIPC is able to 
impact on clinical outcomes in these patient groups. 
  
The infarct-limiting effects of RIPC can also be achieved even if 
the preconditioning protocol is applied after the onset of myo-
cardial ischaemia, a phenomenon which has been labelled remote 
ischaemic postconditioning (RIPost). Although it is not truly a 
postconditioning phenomenon in so much as the intervention is 
usually applied after the onset of myocardial ischaemia and prior 
to myocardial reperfusion, IPost refers to a specifi c strategy for 
modifying the myocardial reperfusion phase itself. Irrespective 
of the terminology, one may expect RIPost to be benefi cial 
to patients presenting with an acute myocardial infarction 
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undergoing primary PCI. Clinical studies are currently underway 
examining this exciting novel treatment strategy.
CONCLUSIONS                                                               
“Conditioning” the heart represents a treatment strategy for 
reducing myocardial injury by harnessing the endogenous ability 
of the heart to protect itself. It can be readily elicited using 
several different approaches: (1) brief episodes of ischaemia and 
reperfusion applied to the heart itself either prior to the index 
ischaemic insult (ischaemic preconditioning, IPC) or at the time 
of myocardial reperfusion (ischaemic postconditioning IPost); 
(2) pharmacological agents which target the signalling pathways 
underlying conditioning (pharmacological preconditioning and 
postconditioning); and fi nally (3) brief episodes of ischaemia and 
reperfusion applied to an organ or tissue distant from the heart 
itself, applied either prior to the index ischaemic insult (remote 
ischaemic preconditioning, RIPC) or after the onset of myocardial 
ischaemia (remote ischaemic postconditioning, RIPost). Depending 
on the clinical situation, “conditioning” the heart has made the 
transition from being a laboratory phenomenon to being a 
potentially benefi cial treatment strategy for patients with coronary 
heart disease.
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